Leveraging knowledge of HDLs major protein ApoA1: Structure, function, mutations, and potential therapeutics

Area of Science:

• Biochemistry
• Molecular Biology
• Cardiovascular Science

Background:

• Apolipoprotein A1 (ApoA1) is essential for high-density lipoprotein (HDL) biogenesis and reverse cholesterol transport.
• HDL particles, facilitated by ApoA1, possess significant cardioprotective properties including anti-inflammatory and anti-atherogenic effects.
• ApoA1's role is being explored in diverse conditions such as diabetes, neurological disorders, cancer, and infectious diseases.

Purpose of the Study:

• To provide a structured overview of Apolipoprotein A1 (ApoA1) protein structure and its functions.
• To review significant ApoA1 mutations and their association with various pathologies.
• To explore the therapeutic potential of ApoA1-based strategies, including peptides and reconstituted HDL (rHDL).

Main Methods:

• Literature review and synthesis of existing research on Apolipoprotein A1 (ApoA1).
• Analysis of reported ApoA1 mutations and their functional consequences.
• Evaluation of current and emerging therapeutic applications of ApoA1, peptides, and rHDL.

Main Results:

• ApoA1's structure and its critical role in reverse cholesterol transport and cardioprotection are elucidated.
• Twenty-four significant ApoA1 mutations linked to various diseases have been identified and reviewed.
• Emerging therapeutic strategies involving beneficial ApoA1 mutations, peptides, and synthetic rHDL show promise.

Conclusions:

• Apolipoprotein A1 (ApoA1) is a multifaceted protein with critical roles in cardiovascular health and beyond.
• Understanding ApoA1 mutations is vital for diagnosing and potentially treating associated diseases.
• Therapeutic development targeting ApoA1, its peptides, and rHDL holds significant potential for future medical interventions.